As I mentioned in the last blog, more and more people are finding ways that CBD products have eased or eliminated health problems. The pool of anecdotal evidence is growing every day. Stories of children whose seizures are cut way back. Reports of cancer patients being relieved of some symptoms and in some cases CBD actually stops cancer cells from multiplying. But, the findings are not all recent. We know that hemp and CBD have been used for millennia for more reasons than you can shake a stick at.
CBD, as I have already pointed out, is not addictive, not psychoactive, and does not have side effects that would cause concern. To top it off, when CBD is used topically or ingested, it kick starts the CBD receptors that are already present in the human body, which in turn help to rev up our immune systems.
It’s also a powerful anti-inflammatory and antioxidant, which is a major benefit for keeping disease at bay.
Why then, pray tell, does the Drug Enforcement Administration (DEA) want to lump it in with all cannabis as a schedule 1 drug?
The official statement goes something like this. DEA spokesperson Russel Bair stated, “It’s an internal accounting mechanism for us. The purpose is to drill down and get more accurate information about research that’s being conducted with CBD in particular.”
Umm, what? Mr. Bair, could you please ’splain it to me so it makes sense? I mean, OK, it’s not considered a medicine, but why would it be classified as a schedule 1 drug when it’s not narcotic, not addictive and not psychoactive?
Now, don’t panic, changing the status of CBD isn’t a done deal, and we’ll keep you posted on the outcome. But really? Don’t you just want to scratch your head and go, Hmmmmm? Or is it just possible that there is a large pharmaceutical company that may want in on the action? Call me cynical, but hmmmmmm.